Predictors of Long‐term Adherence to Evidence‐based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry
Year: 2013
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Despite overall improvements in cardiovascular-disease therapies and outcomes, medication nonadherence remains an important barrier to effective secondary prevention of atherothrombotic disease. HYPOTHESIS: Long-term medication adherence in outpatients with stable atherothrombotic disease is impacted by demographic and clinical factors. METHODS: We examined data from the prospective international Reduction of Atherothrombosis for Continued Health (REACH) Registry. Analyses were derived from 25 737 patients with established atherothrombotic disease with complete adherence data at enrollment and at year 4. Adherence was defined as patients' self-report of taking medications based on class I American College of Cardiology/American Heart Association guidelines for secondary prevention as defined, including antiplatelet agents, statins, and antihypertensive medications. RESULTS: Among patients with atherothrombotic disease, 12 500 (48.6%) were deemed adherent to guideline-recommended medications. Adherent patients were younger, white, and had less polyvascular disease. Hispanic and East Asian patients were less likely to be adherent as compared with white patients (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.59-0.88; and OR: 0.67, 95% CI: 0.53-0.83, respectively). Patients who had a nonfatal MI or underwent coronary angioplasty/stenting during follow-up were more likely to be adherent compared with patients without these events (OR: 1.73, 95% CI: 1.25-2.38; and OR: 2.15, 95% CI: 1.72-2.67, respectively). On the other hand, nonfatal stroke during follow-up was inversely associated with adherence (OR: 0.77, 95% CI: 0.61-0.97). CONCLUSIONS: Using a large international registry of outpatients with atherothrombotic disease, we found that age, region, race/ethnicity, and incident cardiovascular events were predictive of long-term guideline adherence for secondary prevention, suggesting that certain patient groups may benefit from targeted interventions to improve adherence.
Source: Clinical Cardiology
DOI: 10.1002/clc.22217
Authors: Fátima Rodriguez, Christopher P. Cannon, Ph. Gabriel Steg, Dharam J. Kumbhani, Shinya Goto, Sidney C. Smith, Kim A. Eagle, E. Magnus Ohman, Amarachi A. Umez‐Eronini, Elaine Hoffman, Deepak L. Bhatt, on Behalf of the REACH Registry Investigators
Institutions: Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group, Inserm, Hôpital Bichat-Claude-Bernard, Université Paris Diderot, The University of Texas Southwestern Medical Center, Tokai University, University of North Carolina at Chapel Hill, University of Michigan, Michigan Medicine, Duke University, Duke Medical Center, VA Boston Healthcare System
Language: English
Subfield: Family Practice
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Robert Wood Johnson Foundation, American Heart Association, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, William and Flora Hewlett Foundation, Gilead Sciences, CSL Behring, Boston VA Research Institute, Regeneron Pharmaceuticals, Amarin Corporation, Medicines Company, Regado Biosciences, Belvoir Media Group, Abiomed, Daiichi-Sankyo, Eisai, Astellas Pharma, Servier, National Institutes of Health, National Heart, Lung, and Blood Institute, Duke Clinical Research Institute, Daiichi Sankyo Europe
OpenAlex ID: W2128159678
